ES3035041T3 - Compositions and methods for the delivery of therapeutics - Google Patents

Compositions and methods for the delivery of therapeutics

Info

Publication number
ES3035041T3
ES3035041T3 ES17816189T ES17816189T ES3035041T3 ES 3035041 T3 ES3035041 T3 ES 3035041T3 ES 17816189 T ES17816189 T ES 17816189T ES 17816189 T ES17816189 T ES 17816189T ES 3035041 T3 ES3035041 T3 ES 3035041T3
Authority
ES
Spain
Prior art keywords
acid
prodrug
hiv
nanoparticle
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17816189T
Other languages
English (en)
Spanish (es)
Inventor
Benson Edagwa
Howard Gendelman
Brian Johns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska–Lincoln
ViiV Healthcare Co
University of Nebraska System
Original Assignee
University of Nebraska–Lincoln
ViiV Healthcare Co
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska–Lincoln, ViiV Healthcare Co, University of Nebraska System filed Critical University of Nebraska–Lincoln
Application granted granted Critical
Publication of ES3035041T3 publication Critical patent/ES3035041T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES17816189T 2016-06-23 2017-06-22 Compositions and methods for the delivery of therapeutics Active ES3035041T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662353736P 2016-06-23 2016-06-23
PCT/US2017/038693 WO2017223280A2 (en) 2016-06-23 2017-06-22 Compositions and methods for the delivery of therapeutics

Publications (1)

Publication Number Publication Date
ES3035041T3 true ES3035041T3 (en) 2025-08-27

Family

ID=60784694

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17816189T Active ES3035041T3 (en) 2016-06-23 2017-06-22 Compositions and methods for the delivery of therapeutics

Country Status (6)

Country Link
US (1) US11117904B2 (enExample)
EP (3) EP3474857B1 (enExample)
JP (1) JP7160466B2 (enExample)
DK (1) DK4299133T3 (enExample)
ES (1) ES3035041T3 (enExample)
WO (1) WO2017223280A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP4751717A3 (en) * 2018-10-22 2026-08-05 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
WO2020146788A1 (en) * 2019-01-11 2020-07-16 University Of Washington Combination pharmaceutical compositions and methods thereof
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
WO2023183472A1 (en) * 2022-03-23 2023-09-28 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and use thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN120936599A (zh) * 2023-01-18 2025-11-11 歌礼生物科技(杭州)有限公司 整合酶抑制剂及其应用
WO2024227037A1 (en) * 2023-04-26 2024-10-31 University Of Washington Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods
WO2025011661A1 (zh) * 2023-07-12 2025-01-16 歌礼生物科技(杭州)有限公司 整合酶抑制类的制剂及其制备方法
TW202543636A (zh) 2023-12-12 2025-11-16 美商 Viiv 醫療保健公司 結晶形式
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2026012272A1 (en) * 2024-07-12 2026-01-15 Ascletis Bioscience Co., Ltd. Integrase inhibitor and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SMT202100268T1 (it) * 2010-08-05 2021-07-12 Shionogi & Co Metodo per produrre composti aventi attività di inibizione di integrasi di hiv.
TWI577377B (zh) 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
JP2013542945A (ja) 2010-11-02 2013-11-28 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 治療を送達するための組成物および方法
EA030003B1 (ru) * 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
HK1214817A1 (en) 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015127437A1 (en) * 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics

Also Published As

Publication number Publication date
WO2017223280A3 (en) 2019-04-25
EP4299133B1 (en) 2026-07-29
EP3474857B1 (en) 2025-05-21
EP4527463A2 (en) 2025-03-26
JP7160466B2 (ja) 2022-10-25
EP3474857A4 (en) 2020-03-18
EP4299133A2 (en) 2024-01-03
US11117904B2 (en) 2021-09-14
EP3474857C0 (en) 2025-05-21
EP4299133A3 (en) 2024-03-13
EP4527463A3 (en) 2025-06-25
JP2019524670A (ja) 2019-09-05
DK4299133T3 (da) 2026-08-10
EP3474857A2 (en) 2019-05-01
US20210230186A1 (en) 2021-07-29
WO2017223280A2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
EP3474857B1 (en) Compositions and methods for the delivery of therapeutics
US20220211714A1 (en) Compositions and methods for the delivery of therapeutics
ES2970251T3 (es) Profármacos antivirales y nanoformulaciones de los mismos
US12257306B2 (en) Antiviral prodrugs and nanoformulations thereof
US11839623B2 (en) Antiviral prodrugs and formulations thereof
US20170165271A1 (en) Compositions and Methods for the Delivery of Therapeutics
US20220288037A1 (en) Prodrugs and formulations thereof
US20160136105A1 (en) Compositions and Methods for the Delivery of Therapeutics
US11458136B2 (en) Antiviral prodrugs and formulations thereof
US20180028457A1 (en) Compositions and Methods for the Delivery of Therapeutics
BR122024017400A2 (pt) Compostos antivirais, nanopartícula, composição farmacêutica e uso